By using a patented chemotherapeutic galvanostat/potentiostat (CGP) like: The Joey™ from Innovative Potential™, drug molecules work better™ by affording: high-presicion surgical control, expanded reactivity and application options, and increased placement control over pharmaceutical concentration.

​

Work better™ is to have external control over bioactivation and to have improved efficacy versus the precursor compound.

​

An ideal EAC molecule is:

• bioactivatable; and,

• a non-toxic prodrug; and,

• only activated by a CGP, like The Joey™; and

• short-lived but stable enough to be financially valuable; and,

• able to be be stored in fluctuating environmental conditions for a long period of time.

​​​​These qualities make EAC development ideal for cancer treatments, antibiotics, rural markets, pesticides, harsh environments, explosives, and space travel.

By sourcing the drug activation mechanism of actual biological enzymes the EAC process and the patented CGP devices act as artificial enzyme themselves!

​